Advertisement
Advertisement
AGIO
Agios Pharmaceuticals, Inc.
35.14
USDSponsored
+0.22
+0.63%
Apr 17, 16:00 UTC -4
Closed
After-Market
35.13
-0.01
-0.01%
AGIO Earnings Reports
Positive Surprise Ratio
AGIO beat 27 of 40 last estimates.
68%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$14.26M
/-$1.84
Implied change from Q4 25 (Revenue/ EPS)
-28.68%
/-1.08%
Implied change from Q1 25 (Revenue/ EPS)
+63.47%
/+18.71%
Agios Pharmaceuticals, Inc. earnings per share and revenue
On Feb 12, 2026, AGIO reported earnings of -1.86 USD per share (EPS) for Q4 25, beating the estimate of -1.98 USD, resulting in a 6.31% surprise. Revenue reached 20.00 million, compared to an expected 12.25 million, with a 63.21% difference. The market reacted with a +1.30% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -1.84 USD, with revenue projected to reach 14.26 million USD, implying an decrease of -1.08% EPS, and decrease of -28.68% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
What were Agios Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Agios Pharmaceuticals, Inc. reported EPS of -$1.86, beating estimates by 6.31%, and revenue of $20.00M, 63.21% above expectations.
How did the market react to Agios Pharmaceuticals, Inc.'s Q4 2025 earnings?
The stock price moved up 1.3%, changed from $27.71 before the earnings release to $28.07 the day after.
When is Agios Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Agios Pharmaceuticals, Inc.'s next earnings report?
Based on 7
analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.84 and revenue of $14.26M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement